Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

Summary

The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.

Timeline

Start

2022-03-15

Primary completion

2024-07-02

Completion

2024-07-02

Publications

• Antinew J, Fountaine RJ, Loprinzo V, Straghan E, Dubrovin S, DeBesi P, Vatakis N, Fullerton T. A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention. J Headache Pain. 2025 Dec 9;27(1):17. doi: 10.1186/s10194-025-02225-7.

Drugs

Indications